Moderate to Severe Plaque PsoriasisPROMPTNCT05155098
2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis
An observational study of Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis, run by Novartis Pharmaceuticals at 10 sites in Thailand.
Trial summary
This was an observational, prospective primary data collection study. The duration of observation was 2 years after study enrolment date. Disease and treatment history were retrospectively reviewed from medical record at enrollment with no time limits for the key diagnosis of enrolment (plaque psoriasis, psoriatic… Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis
- What is being tested?
- secukinumab
- How many people
- 127 participants
- Where
- 10 sitesThailand
- Study dates
- 25 Mar 2022to 20 Aug 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients with moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis
Who may be able to join
- Written informed consent of the patient to participate in the study
- Age 18-80 years.
- Patients with an assured diagnosis by the treating physician of active moderate to severe plaque psoriasis or active PsA or active AS or active non-radiographic axial SpA.
- Patients must have received the official approval to receive secukinumab in Dermatology Disease Prior Authorization (DDPA) or Rheumatology Disease Prior Authorization (RDPA) before study participation or the decision to treat patient's condition with secukinumab is happened before entering the study
- Patients must receive the first dose of secukinumab during the study enrollment period.
- Patients for whom the decision for a therapy with secukinumab is made by the attending treating physician, regardless of this non-interventional study.
- Patients who have EQ-5D score before start the 1st dose secukinumab.
Who cannot join
- Any medical or psychological condition in the treating physician's opinion which may prevent the patient from study participation for the 2 year study period.*
- Patients participating in parallel in other interventional clinical trial.
- Patients participated in an interventional clinical trial with secukinumab involvement in the past.
- Note: For example, patients diagnosed with a terminal illness and those with cognitive impairment due to dementia and Alzheimer's disease.
Trial locations and contacts
10 sites in 1 country.
10 sites in 1 country
Thailand10 sites
Novartis Investigative Site
Bangkok, 10300
Novartis Investigative Site
Bangkok, 10330
Novartis Investigative Site
Bangkok, 10400
Novartis Investigative Site
Bangkok, 10700
Novartis Investigative Site
Chiang Mai, 50200
Novartis Investigative Site
Kaen, 40000
Novartis Investigative Site
Khon Kaen, THA, 40002
Novartis Investigative Site
Muang, Thailand, 12120
Novartis Investigative Site
Nakhon Ratchasima, 30000
Novartis Investigative Site
Songkhla, Hat Yai, 90110
About this study
Official title: 2 Years Prospective Study to Collect Real-life Data On the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial spondyloarthriTis (PROMPT)
This was an observational, prospective primary data collection study. The duration of observation was 2 years after study enrolment date. Disease and treatment history were retrospectively reviewed from medical record at enrollment with no time limits for the key diagnosis of enrolment (plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthropathy).
Read the detailed description
After the baseline visit, data was collected for each patient prospectively every 6 months for up to 2 years. At each visit, effectiveness parameters, as well as the patients' QoL and treatment pattern were documented.
- Conditions
- Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis
- Being tested
- secukinumab
- Keywords
- Moderate to severe plaque psoriasis, Psoriatic arthritis, Ankylosing spondylitis, Non-radiographic axial spondyloarthritis, NIS, Thailand, secukinumab
- Medical subject headings
- Arthritis, Psoriatic, Spondylitis, Ankylosing, Non-Radiographic Axial Spondyloarthritis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
secukinumabOther
Prospective observational study. There is no treatment allocation. Patients who are receiving or intend to receive secukinumab are eligible to enroll into this study.
| Study group | Role | What they receive |
|---|---|---|
| secukinumab | Patients receiving secukinumab in real world practice Receives: Other: secukinumab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Retention rate of secukinumab therapy
Retention rate is defined as percentage of patients who have not discontinued the medication.
Measured: 2 years
Secondary outcomes (33)
Retention rate of secukinumab therapy by individual indication
Retention rate is defined as percentage of patients who have not discontinued the medication.
Measured: year 1, year 2
Change in QoL by EQ-5D Visual Analog Scale (VAS)
Euro-QoL-5 Dimension Questionnaire (EQ-5D) is a standardized participant completed questionnaire that measures health-related quality of life and translates that score into an index value or utility score. EQ-5D health state profile is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1= no problems, 2= slight problems, 3=moderate problems, 4= severe problems, and 5= extreme problems. Higher scores indicated greater levels of problems across each of the five dimensions.
Measured: Baseline, month 6, month 12, month 18, month 24
Treatment pattern
Proportion of patients for each indication with alterations of secukinumab treatment regimen and reasons for.
Measured: Month 6, month 12, month 18, month 24
Work/school absenteeism
Number of days of absenteeism from work/school due to health condition during each visit. Health condition which is considered to be related to the absenteeism will be determined by the treating physicians on the relationship with psoriasis, psoriatic arthritis or non-radiographic axial SpA or others conditions.
Measured: 2 years
Patients with Psoriasis: Proportions of patients achieving a PASI 75, 90, and 100 responses
Psoriasis Area and Severity Index (PASI) takes into account the extent of the disease, as well as the severity of erythema, scaling, and thickness in different body areas affected by psoriasis.
- A PASI 75 represents an improvement in the PASI score of at least 75% as compared with baseline.
- A PASI 90 represents an improvement in the PASI score of at least 90% as compared with baseline.
- A PASI 100 response corresponds to complete clearing of psoriasis (PASI = 0).
Measured: Month 6, month 12, month 18, month 24
Patients with Psoriasis: Changes between PASI response categories over time
Changes between PASI response categories over time after starting participation in the study to be collected.
Measured: 2 Years
Patients with Psoriasis: Absolute PASI scores
Absolute PASI scores to be collected
Measured: Month 6, month 12, month 18, month 24
Patients with Psoriasis: Changes in absolute and relative PASI scores over time
Relative PASI, also called PASI response, is reported as a percent change from baseline PASI.
Absolute PASI is reported as a score to reflect the current status of severity of disease.
Measured: Baseline, month 6, month 12, month 18, month 24
Patients with Psoriasis: Proportion of patients achieving a PGA 0/1 response
Physician Global Assessment (PGA) 0/1 response = clear/almost clear skin
Measured: Month 6, month 12, month 18, month 24
Patients with Psoriasis: Proportion of patients achieving a DLQI 0/1 response
Dermatology Life Quality Index (DLQI) is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such psoriasis. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) 1 ( a little) to 3 (very much). "Not relevant" is a valid score also and is scored as 0.
Measured: Month 6, month 12, month 18, month 24
Patients with Psoriasis: Correlation between PASI and DLQI score
Correlation analysis will be performed using Pearson's correlation or Spearman's correlation, depending on normality.
Measured: 2 years
Patients with Psoriatic Arthritis: 78 TJC and 76 SJC
78 tender joint count (TJC) is determined by physical examination of 78 joint counts that are assessed for tenderness.
76 swollen joint count (SJC) is determined by physical examination of 76 joint counts that are classified as either swollen or not swollen.
Measured: 1 year, 2 years
Patients with Psoriatic Arthritis: Physician's global assessment (PGA)
VAS scale will be used to measure disease activity. The Visual Analog Scale (VAS) is a commonly used measurement of pain, discomfort, that goes from 0 meaning no pain to 100 meaning worst imaginable pain
Measured: 1 year, 2 years
Patients with Psoriatic Arthritis: Total patient pain assessed by visual analog scale (VAS)
The Visual Analog Scale (VAS) is a commonly used measurement of pain, discomfort, that goes from 0 meaning no pain to 100 meaning worst imaginable pain
Measured: 1 year, 2 years
Patients with Psoriatic Arthritis: Presence of any dactylitis
Dactylitis is severe inflammation of the finger and toe joints.
Measured: 1 year, 2 years
Patients with Psoriatic Arthritis: Presence of any enthesitis
Presence of any enthesitis in the following sites: lateral epicondyle humerus left and right, Achilles left and right and medial condyle femur left and right.
Enthesitis refers to inflammation of entheses, the site where ligaments or tendons insert into the bones.
Measured: 1 year, 2 years
Patients with Psoriatic Arthritis: Appearance of new bone erosions or worsening of pre-existing erosions
Appearance of new bone erosions or worsening of pre-existing erosions in the hands and feet by X-ray assessment, according to the Treating Physician's opinion
Measured: 1 year, 2 years
Patients with Psoriatic Arthritis: Proportion of patients achieving a PASI 75, 90, and 100 response
Psoriasis Area and Severity Index (PASI) takes into account the extent of the disease, as well as the severity of erythema, scaling, and thickness in different body areas affected by psoriasis.
- A PASI 75 represents an improvement in the PASI score of at least 75% as compared with baseline.
- A PASI 90 represents an improvement in the PASI score of at least 90% as compared with baseline.
- A PASI 100 response corresponds to complete clearing of psoriasis (PASI = 0).
Measured: month 6, month 12, month 18 and month 24
Patients with Psoriatic Arthritis: Changes between PASI response categories over time
Changes between PASI response categories over time after starting participation in the study
Measured: 2 years
Patients with Psoriatic Arthritis: Absolute PASI scores
Absolute PASI scores to be collected
Measured: month 6, month 12, month 18 and month 24
Patients with Psoriatic Arthritis: Changes in absolute and relative PASI scores over time
Changes in absolute and relative PASI scores over time after inclusion into the study.
Measured: 2 years
Patients with Psoriatic Arthritis: Changes of HAQ-DI score
Health Assessment Questionnaire Disability Index (HAQ-DI) assesses a subject's level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities. There are 20 questions in 8 categories of functioning including dressing, rising, eating, walking, hygiene, reach, grip and usual activities. The stem of each item asks 'Over the past week, "are you able to..." perform a particular task'. Each item is scored on a 4 point scale from 0 - 3, representing normal, no difficulty (0), some difficulty (1), much difficulty (2) and unable to do (3). The disability index score is calculated as the mean of the available category scores, ranging from 0 to 3. A negative change from baseline indicates improvement.(Only at sites where HAQ-DI score is part of clinical routine).
Measured: month 6, month 12, month 18 and month 24
Patients with Psoriatic Arthritis: Changes of FACIT-Fatigue score
The Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) assesses self-reported fatigue and its impact upon daily activities and function.
FACIT-Fatigue Scale: overall score (0 to 52)=the sum of scores for 13 questions. For each question, par. rated their condition for the past week on a 5-point scale: 0 (not at all) to 4 (very much). A high score indicates low fatigue.
(Only at sites where FACIT-Fatigue score is part of clinical routine).
Measured: month 6, month 12, month 18 and month 24
Patients with Psoriatic Arthritis: Correlation between effectiveness measures, HAQ-DI, and FACIT-Fatigue scores
Correlation analysis will be performed using Pearson's correlation or Spearman's correlation, depending on normality.
Measured: 2 years
Patients with Ankylosing spondylitis: Bath AS disease activity index (BASDAI) response
BASDAI is a participant-reported assessment consisting of 6 questions that relate to 5 major symptoms relevant to ankylosing spondylitis: 1) Fatigue, 2) Spinal pain, 3) Peripheral arthritis, 4) Enthesitis, 5) Intensity, and 6) Duration of morning stiffness. Participants need to score each item with a score from 0 to 10. Total score is obtained from the average of symptom scores ranging 0 (no problem) to 10 (worst problem), with a higher score indicating more severe symptoms.
Measured: year 1, year 2
Patients with Ankylosing spondylitis: Patient's global assessment of disease activity
Patient's global assessment of disease activity will be measured using VAS scale or NRS (numeric rating scale). NRS scale goes from 0 to 10 (0= no activity, 10= activity)
Measured: year 1, year 2
Patients with Ankylosing spondylitis: C-reactive protein (CRP) or high-sensitivity CRP (hsCRP)
CRP or high-sensitivity CRP to be collected
Measured: year 1, year 2
Patients with Ankylosing spondylitis: Total spinal pain assessed using VAS scale
The Visual Analog Scale (VAS) is a commonly used measurement of pain, discomfort, that goes from 0 meaning no pain to 100 meaning worst imaginable pain
Measured: year 1, year 2
Patients with Ankylosing spondylitis: Presence of any enthesitis
Presence of any enthesitis in the following sites:
- Costochondral 1 right/left
- Costochondral 7 right/left
- Spina iliaca anterior superior right/left
- Crista iliaca right/left
- Spina iliaca posterior right/left
- Processus spinosus L5
- Achilles tendon, insertion right/left Enthesitis refers to inflammation of entheses, the site where ligaments or tendons insert into the bones.
Measured: 2 years
Patients with Ankylosing spondylitis: Appearance or worsening of lesions at anterior sites of the vertebrae assessed by X-ray
Appearance or worsening, according to the treating physician's opinion, of any of the following lesions at anterior sites of the vertebrae assessed by X-ray (when available):
- Squaring
- Erosions
- Sclerosis
- Syndesmophytes
- Bridging syndesmophytes
Measured: year 1, year 2
Patients with Ankylosing spondylitis: Appearance or worsening of bone marrow edema (BME) in the spine and/or sacro-iliac joints assessed by magnetic resonance imaging (MRI)
Appearance or worsening (according to the Treating Physician's opinion) of bone marrow edema (BME) in the spine and/or sacro-iliac joints assessed by magnetic resonance imaging (MRI) (when available).
Measured: year 1, year 2
Ankylosing spondylitis and non-radiographic axial SpA: Changes of FACIT-Fatigue score compared to baseline
The Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) assesses self-reported fatigue and its impact upon daily activities and function.
FACIT-Fatigue Scale: overall score (0 to 52)=the sum of scores for 13 questions. For each question, par. rated their condition for the past week on a 5-point scale: 0 (not at all) to 4 (very much). A high score indicates low fatigue.
Measured: month 6, month 12, month 18 and month 24
Ankylosing spondylitis: Correlation between ASDAS, BASDAI, and FACIT-Fatigue scores
Data from BASDAI, patient's global assessment (NRS) and CRP/hsCRP can be used to calculate the AS disease activity score (ASDAS).
Correlation analysis will be performed using Pearson's correlation or Spearman's correlation, depending on normality.
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Dec 2021
- Study start25 Mar 2022
- Primary completion20 Aug 2025
- Study completion20 Aug 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Moderate to Severe Plaque PsoriasisStudies of the same condition, open and under way.
- More trials run by Novartis PharmaceuticalsThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 127 participants (actual)
Sponsor and investigators
- Lead sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Novartis Pharmaceuticals, Study director, Novartis Pharmaceuticals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05155098
- Sponsor's protocol ID
- CAIN457ATH02
- Acronym
- PROMPT
- Status last verified
- Nov 2025
- First submitted
- 30 Nov 2021
- Last updated
- 23 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- 2 Years Prospective Study to Collect Real-life Data On the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial spondyloarthriTis (PROMPT)
- ClinicalTrials.gov ID
- NCT05155098
- Acronym / sponsor ID
- PROMPT / CAIN457ATH02
- Conditions
- Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis
- Keywords
- Moderate to severe plaque psoriasis, Psoriatic arthritis, Ankylosing spondylitis, Non-radiographic axial spondyloarthritis, NIS, Thailand, secukinumab
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 127 participants (actual)
- Lead sponsor
- Novartis PharmaceuticalsIndustry (pharma, biotech, devices)
- Study start
- 25 Mar 2022 (actual)
- Primary completion
- 20 Aug 2025 (actual)
- Study completion
- 20 Aug 2025 (actual)
- First posted
- 13 Dec 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This was an observational, prospective primary data collection study. The duration of observation was 2 years after study enrolment date. Disease and treatment history were retrospectively reviewed from medical record at enrollment with no time limits for the key diagnosis of enrolment (plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthropathy).
Detailed description
After the baseline visit, data was collected for each patient prospectively every 6 months for up to 2 years. At each visit, effectiveness parameters, as well as the patients' QoL and treatment pattern were documented.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| secukinumab | – | Other: secukinumabPatients receiving secukinumab in real world practice |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients with moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis
Key inclusion criteria (7 listed)
- Written informed consent of the patient to participate in the study
- Age 18-80 years.
- Patients with an assured diagnosis by the treating physician of active moderate to severe plaque psoriasis or active PsA or active AS or active non-radiographic axial SpA.
- Patients must have received the official approval to receive secukinumab in Dermatology Disease Prior Authorization (DDPA) or Rheumatology Disease Prior Authorization (RDPA) before study participation or the decision to treat patient's condition with secukinumab is happened before entering the study
- Patients must receive the first dose of secukinumab during the study enrollment period.
Key exclusion criteria (4 listed)
- Any medical or psychological condition in the treating physician's opinion which may prevent the patient from study participation for the 2 year study period.*
- Patients participating in parallel in other interventional clinical trial.
- Patients participated in an interventional clinical trial with secukinumab involvement in the past.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| secukinumabProspective observational study. There is no treatment allocation. Patients who are receiving or intend to receive secukinumab are eligible to enroll into this study. | Other | secukinumab |
Primary outcome
Retention rate of secukinumab therapy
Time frame: 2 years
Retention rate is defined as percentage of patients who have not discontinued the medication.
33 secondary outcomes
Retention rate of secukinumab therapy by individual indication
Time frame: year 1, year 2
Change in QoL by EQ-5D Visual Analog Scale (VAS)
Time frame: Baseline, month 6, month 12, month 18, month 24
Treatment pattern
Time frame: Month 6, month 12, month 18, month 24
Work/school absenteeism
Time frame: 2 years
Patients with Psoriasis: Proportions of patients achieving a PASI 75, 90, and 100 responses
Time frame: Month 6, month 12, month 18, month 24
Patients with Psoriasis: Changes between PASI response categories over time
Time frame: 2 Years
Patients with Psoriasis: Absolute PASI scores
Time frame: Month 6, month 12, month 18, month 24
Patients with Psoriasis: Changes in absolute and relative PASI scores over time
Time frame: Baseline, month 6, month 12, month 18, month 24
Patients with Psoriasis: Proportion of patients achieving a PGA 0/1 response
Time frame: Month 6, month 12, month 18, month 24
Patients with Psoriasis: Proportion of patients achieving a DLQI 0/1 response
Time frame: Month 6, month 12, month 18, month 24
Patients with Psoriasis: Correlation between PASI and DLQI score
Time frame: 2 years
Patients with Psoriatic Arthritis: 78 TJC and 76 SJC
Time frame: 1 year, 2 years
Patients with Psoriatic Arthritis: Physician's global assessment (PGA)
Time frame: 1 year, 2 years
Patients with Psoriatic Arthritis: Total patient pain assessed by visual analog scale (VAS)
Time frame: 1 year, 2 years
Patients with Psoriatic Arthritis: Presence of any dactylitis
Time frame: 1 year, 2 years
Patients with Psoriatic Arthritis: Presence of any enthesitis
Time frame: 1 year, 2 years
Patients with Psoriatic Arthritis: Appearance of new bone erosions or worsening of pre-existing erosions
Time frame: 1 year, 2 years
Patients with Psoriatic Arthritis: Proportion of patients achieving a PASI 75, 90, and 100 response
Time frame: month 6, month 12, month 18 and month 24
Patients with Psoriatic Arthritis: Changes between PASI response categories over time
Time frame: 2 years
Patients with Psoriatic Arthritis: Absolute PASI scores
Time frame: month 6, month 12, month 18 and month 24
Patients with Psoriatic Arthritis: Changes in absolute and relative PASI scores over time
Time frame: 2 years
Patients with Psoriatic Arthritis: Changes of HAQ-DI score
Time frame: month 6, month 12, month 18 and month 24
Patients with Psoriatic Arthritis: Changes of FACIT-Fatigue score
Time frame: month 6, month 12, month 18 and month 24
Patients with Psoriatic Arthritis: Correlation between effectiveness measures, HAQ-DI, and FACIT-Fatigue scores
Time frame: 2 years
Patients with Ankylosing spondylitis: Bath AS disease activity index (BASDAI) response
Time frame: year 1, year 2
Patients with Ankylosing spondylitis: Patient's global assessment of disease activity
Time frame: year 1, year 2
Patients with Ankylosing spondylitis: C-reactive protein (CRP) or high-sensitivity CRP (hsCRP)
Time frame: year 1, year 2
Patients with Ankylosing spondylitis: Total spinal pain assessed using VAS scale
Time frame: year 1, year 2
Patients with Ankylosing spondylitis: Presence of any enthesitis
Time frame: 2 years
Patients with Ankylosing spondylitis: Appearance or worsening of lesions at anterior sites of the vertebrae assessed by X-ray
Time frame: year 1, year 2
Patients with Ankylosing spondylitis: Appearance or worsening of bone marrow edema (BME) in the spine and/or sacro-iliac joints assessed by magnetic resonance imaging (MRI)
Time frame: year 1, year 2
Ankylosing spondylitis and non-radiographic axial SpA: Changes of FACIT-Fatigue score compared to baseline
Time frame: month 6, month 12, month 18 and month 24
Ankylosing spondylitis: Correlation between ASDAS, BASDAI, and FACIT-Fatigue scores
Time frame: 2 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Oct 2026.
- Link to study resultsLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Moderate to Severe Plaque Psoriasis
RecruitingPhase 3
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis
Plaque Psoriasis
RecruitingPhase 2
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
Plaque Psoriasis
Not yet recruitingObservational study
A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy
Plaque Psoriasis
RecruitingPhase 2
An Open-label Study of HS-20137 in Participants With Moderate-to-Severe Plaque Psoriasis
Moderate-to-severe Plaque Psoriasis
Not yet recruitingPhase 3
A Study of Zasocitinib in Adults With Non-pustular Palmoplantar Psoriasis
Palmoplantar Psoriasis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Novartis Pharmaceuticals study director
Novartis Pharmaceuticals
10 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis, run by Novartis Pharmaceuticals at 10 sites in Thailand.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 10 sites in Thailand. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Retention rate of secukinumab therapy (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Oct 2026.